Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

NCT00225290 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

230

Enrollment

INDUSTRY

Sponsor class

Stopped slowly recruitment rate

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Thalidomide(Thado)

Sponsor

TTY Biopharm